Ensign Peak Advisors, Inc Prometheus Biosciences, Inc. Transaction History

Ensign Peak Advisors, Inc

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$103.46 - $126.29 $853,545 - $1.04 Million	8,250 Added 4.88%	177,457 $19 Million
Q4 2022 Feb 13, 2023	BUY	$36.06 - $117.21 $3.67 Million - $11.9 Million	101,750 Added 150.84%	169,207 $18.6 Million
Q3 2022 Nov 14, 2022	BUY	$28.17 - $59.01 $1.86 Million - $3.89 Million	65,897 Added 4224.17%	67,457 $3.98 Million
Q1 2022 May 16, 2022	BUY	$30.13 - $50.0 $47,002 - $78,000	1,560 New	1,560 $59,000

29.6K

Ticker RXDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,904,100
Description
Prometheus Biosciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics and companion diagnostics products for the treatment of inflammatory bowel diseases (IBD). Its lead product includes PRA023, a humanized IgG1 monoclonal antibody (mAb), which is in Phase IIa clinical trial...

Get notified when there are updates to the investment portfolio of Ensign Peak Advisors, Inc, based on Form 13F filings with the SEC.

Stay updated on Ensign Peak Advisors, Inc with notifications on news.